Disease · MONDO_0020325

anaplastic large cell lymphoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. anaplastic large cell lymphoma. Diseases, record MONDO_0020325. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0020325

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: anaplastic large cell lymphoma; Open Targets
Open Targets ID: MONDO_0020325; Open Targets
Other names: ALCL, CD30 Positive anaplastic large cell lymphoma, Ki-1 lymphoma, Ki-1 positive anaplastic large cell lymphoma, Ki-1+ ALCL, Ki-1+ anaplastic large cell lymphoma, primary systemic ALCL, sACL; Open Targets
Disease Ontology: DOID:0050744; Disease Ontology
MeSH: D017728; MeSH
NCI Thesaurus: C3720; NCI Thesaurus
Orphanet: ORPHA:98841; Orphanet
Highest stage of its drugs: Approval, for 2 of its 65 drugs, from DailyMed, PMDA and TTD; Open Targets

Drugs65

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BRENTUXIMAB VEDOTIN	CHEMBL1742994	Antibody drug conjugate	Approval	DailyMed and PMDA	12	10	10	Drugs and targets
BRIGATINIB	CHEMBL3545311	Small molecule	Approval	TTD	4	3	3	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
CYTARABINE	CHEMBL803	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
IFOSFAMIDE	CHEMBL1024	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets

1 to 10 of 65

See all 65 drugs

Targets132

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TOP2A	DNA topoisomerase 2-alpha	8	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 3	https://conductscience.org/library/genes/7153	Drugs and targets
TUBA1A	Tubulin	6	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	6	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	6	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	6	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	6	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	6	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	6	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	6	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	6	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7280	Drugs and targets

1 to 10 of 132

See all 132 targets

Trials55

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02139592	Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"		292	2019-05-06	Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma	BRENTUXIMAB VEDOTIN	Its record names the disease	ClinicalTrials.gov
NCT01979536	Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma	Phase 2	137	2022-07-06	Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma	BRENTUXIMAB VEDOTIN, CRIZOTINIB	Its record names the disease	ClinicalTrials.gov
NCT01578499	A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)	Phase 3	131	2018-03-16	Primary Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Cutaneous T-Cell Lymphoma	BRENTUXIMAB VEDOTIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00059839	Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma	Phase 3	129	2013-10-08	Lymphoma	DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PREDNISONE, VINBLASTINE, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00939770	Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Phase 1/2	122	2020-05-05	Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma	CRIZOTINIB	Its record names the disease	ClinicalTrials.gov
NCT03493451	Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms	Phase 2	77	2022-05-04	Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK T Cell Lymphoma, Extranodal NK T Cell Lymphoma, Nasal, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma Refractory, Peripheral T-cell Lymphoma NOS, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Peripheral T-Cell Lymphoma Refractory, Anaplastic Large Cell Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, ALK-negative Anaplastic Large Cell Lymphoma, ALK-Positive Anaplastic Large Cell Lymphoma, Cutaneous T-cell Lymphoma	TISLELIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02561273	Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma	Phase 1/2	54	2021-06-18	Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Stage II Angioimmunoblastic T-cell Lymphoma, Stage II Enteropathy-Associated T-Cell Lymphoma, Stage III Angioimmunoblastic T-cell Lymphoma, Stage III Enteropathy-Associated T-Cell Lymphoma, Stage IV Angioimmunoblastic T-cell Lymphoma, Stage IV Enteropathy-Associated T-Cell Lymphoma	CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, LENALIDOMIDE, PREDNISONE, VINCRISTINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT01606878	Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Phase 1	46	2024-01-05	Childhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Neuroblastoma	CRIZOTINIB	Its record names the disease	ClinicalTrials.gov
NCT01492088	Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma	Phase 1/2	36	2017-05-15	Relapsed or Refractory Hodgkin Lymphoma, Relapsed or Refractory Anaplastic Large-cell Lymphoma	BRENTUXIMAB VEDOTIN	Its record names the disease	ClinicalTrials.gov
NCT03049449	T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas	Phase 1	26	2022-05-25	Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Extranodal NK-T-Cell, Lymphoma, T-Cell, Peripheral	CYCLOPHOSPHAMIDE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 55

See all 55 trials

Comparisons in its trials9

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm BV (Brentuximab Vedotin, Combination Chemotherapy) vs Arm CZ (Crizotinib, Combination Chemotherapy): deaths from any cause	3 of 68	3 of 68	136	NCT01979536	Trial comparisons
Arm BV (Brentuximab Vedotin, Combination Chemotherapy) vs Arm CZ (Crizotinib, Combination Chemotherapy): serious adverse events	24 of 68	41 of 68	136	NCT01979536	Trial comparisons
Brentuximab Vedotin vs Methotrexate or Bexarotene: deaths from any cause	22 of 66	25 of 62	128	NCT01578499	Trial comparisons
Brentuximab Vedotin vs Methotrexate or Bexarotene: serious adverse events	18 of 66	18 of 62	128	NCT01578499	Trial comparisons
Standard (APO) With Vincristine (Arm I) vs Consolidation (Includes Vinblastine) (Arm II): serious adverse events	2 of 64	4 of 61	125	NCT00059839	Trial comparisons
Treatment (10 mg Lenalidomide) vs Treatment (15 mg Lenalidomide): deaths from any cause	9 of 39	1 of 4	43	NCT02561273	Trial comparisons
Treatment (10 mg Lenalidomide) vs Treatment (15 mg Lenalidomide): serious adverse events	14 of 39	2 of 4	43	NCT02561273	Trial comparisons
Phase 2: Part B: PF-02341066 280 mg/m2/Dose BID vs Phase 2: Part C: PF-02341066 280 mg/m2/Dose BID: Number of Participants (Relapsed or Refractory Neuroblastoma or Anaplastic Large Cell Lymphoma (ALCL)) With Response to Crizotinib	1 of 14	7 of 10	24	NCT00939770	Trial comparisons
Brentuximab Vedotin 1.4 mg/kg: Phase 1 vs Brentuximab Vedotin 1.8 mg/kg: Phase 1: Number of Participants With Clinically Significant Vital Signs Values Reported as AEs (Phase 1)	0 of 3	0 of 9	12	NCT01492088	Trial comparisons

Papers from its trials46

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35914224	RESULT	1	PubMed
32987765	RESULT	1	PubMed
32730187	RESULT	2	PubMed
32661576	RESULT	1	PubMed
28787259	RESULT	1	PubMed
28273702	RESULT	1	PubMed
21444917	RESULT	1	PubMed
21280197	RESULT	1	PubMed
20679620	RESULT	2	PubMed
19466965	RESULT	1	PubMed

1 to 10 of 46

See all 46 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0020325

GET https://conductscience.org/api/diseases/v1/MONDO_0020325/drugs?page=2

API reference For AI assistants